IBA Business Update – Third Quarter 2021
18 November 2021 - 7:00AM
IBA Business Update – Third Quarter 2021
Louvain-La-Neuve, Belgium, November 18,
2021 – IBA (Ion Beam Applications S.A., EURONEXT), the
world leader in particle accelerator technology, today announces
its business update for the third quarter ending 30 September
2021.
Group Overview
- Strong performance across all business lines
- Ongoing commitment to stakeholder approach, delivering the best
offering to our customers and investing for long-term sustainable
growth whilst meeting ESG targets
- Strong balance sheet maintained, with EUR 91 million unaudited
net cash (30 June 2021: EUR 69 million)
Olivier
Legrain, Chief Executive Officer of IBA commented: “IBA
has continued to perform strongly in the second half of 2021 with
solid progress across all business units. We have a highly active
pipeline of new opportunities and are particularly excited about
the marked revival in proton therapy activity in the important US
market. Our Other Accelerators and Dosimetry businesses have also
been exceptionally strong in the second half of the year with
encouraging momentum as we approach 2022.
“A core component of our roadmap towards
sustainable growth is investment in future innovation to deliver
strategic impact. In this regard, we were pleased to provide
updates on a range of initiatives at the recent ASTRO conference,
as well as several strategic partnerships, including in the
promising field of radiotherapeutics. We are very excited about
future prospects across our business lines and are in a confident
position to achieve long-term profitability, with our stakeholder
approach underpinning all of our business activities.”
Business Unit Highlights (including
post-period end)
Proton Therapy
- 13 Proteus®ONE1 and 8 Proteus®PLUS1 projects currently ongoing.
Strong pipeline of new global opportunities with significant
activity in the US and Asia
- Contract signed for a five room Proteus®PLUS System in China
including a multi-year service contract
- Post-period end, finalized contract with Advocate Radiation
Oncology in Florida, which previously selected IBA’s Proteus®ONE
for its new Radiation Oncology Centre, including a multi-year
service contract
- Post-period end, announced updates at ASTRO, including
expansion of strategic partnership with RaySearch within Flash and
proton ARC therapy projects, and the launch of Campus, the world’s
first online proton therapy platform
Other Accelerators (RadioPharma,
Industrial) and Dosimetry
- Strong performance in Other Accelerators in the third quarter,
with 23 machines sold in the year to date of which 11 machines were
sold in Asia
- Strategic R&D partnership announced with SCK CEN to enable
the production of Actinimum-225 (Ac-225), a novel therapeutic
radioisotope which has significant potential in the treatment of
cancer
- Post-period end, announced a strategic partnership with TRAD
Tests & Radiations to enable the development of a new radiation
processing module, addressing an increasing unmet need in the
sterilization market
- Dosimetry revenues and order book have continued to strengthen,
further demonstrating the success of the business unit’s recent
product launches
Outlook During the third
quarter of 2021, IBA’s performance has continued to accelerate with
strong progress across all business lines. Our pipeline is very
active, particularly in the US and in Asia, and, coupled with the
robust balance sheet and predictable revenue base of the services
business, provides encouraging visibility for the period ahead.
Whilst we are confident about business performance, the ongoing
complex situation with the pandemic means that we are still unable
to provide reliable financial guidance. We will provide a further
update at the time of the 2021 full year results in March 2022.
***ENDS***
Shareholder's Agenda
Full Year
Results
24 March 2022Business Update First Quarter
2022
19 May 2022General
Assembly
8 June 2022Half Year 2022
Results
31 August 2022Business Update Third Quarter
2022
17 November 2022
Directors' Declarations
In accordance with the Royal Decree of 14
November 2007, IBA indicates that this Trading Update has been
prepared by the Chief Executive Officer (CEO) and the Chief
Financial Officer (CFO).
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,500 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
CONTACTS
Soumya
ChandramouliChief Financial Officer+32 10
475 890Investorrelations@iba-group.com
Olivier LechienCorporate
Communication Director+32 10 475 890communication@iba-group.com
Consilium Strategic
CommunicationsAmber Fennell, Angela Gray, Lucy
Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com
1 *Proteus®ONE and Proteus®PLUS are brand names of Proteus
235
- 211118-IBA-Q3-business-update-EN
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Apr 2023 bis Apr 2024